Does MK-677 Require Post Cycle Therapy?

In this article, we will take a close look at the relationship between MK-677, also known as Ibutamoren, and post cycle therapy (PCT). We will understand the reasons why MK-677 does not require PCT, unlike anabolic steroids, and the implications this has for bodybuilders and those using performance-enhancing drugs.
Klara Hatinova

Klara Hatinova

Klara is postgraduate researcher in experimental psychology at the
University of Oxford.

A blue image with text saying "Does MK-677 Require Post Cycle Therapy?"

Does MK-677 Require Post Cycle Therapy?

No, MK-677 does not require post cycle therapy. This is because it does not suppress natural hormone production, unlike anabolic steroids. Therefore, there is no need for recovery or rebalancing of hormones post usage.

What is PCT?

Post cycle therapy (PCT) is a term often used in the context of bodybuilding. It refers to a period of medication treatment or compensatory behaviour that follows the use of anabolic steroids.

However, it is important to acknowledge that the abbreviation PCT can also be used for many other things, including procalcitionin, postcoital test, or post calving tonic. In the medical field, PCT can refer to different procedures depending on the context.

What is PCT Used for?

PCT is often used after completing a SARMs cycle (selective androgen receptor modulators) or after general performance and image-enhancing drugs (PIEDs) to reduce side effects of the PIEDs, prevent exacerbation of side effects and reduce symptoms of withdrawal [1, 2]. For example, individuals may use PCT to overcome mood swings after discontinuing PIEDs, reduce testicle shrinkage, restore natural testosterone levels and erectile dysfunction, or maintain enhanced performance. PCT can also prevent other health risks of a prolonged SARMs cycle, including risks of prostate cancer.

What is MK-677?

MK-677, also known as Ibutamoren, is an oral ghrelin mimetic and growth hormone secretagogue. It stimulates the secretion of human growth hormone (GH) from the pituitary gland and increases IGF-1 levels [3].

In the context of bodybuilding, MK-677 is often used for its potential to increase muscle gain and protein synthesis. Studies have shown that daily administration of MK-677 can significantly increase fat-free mass, which includes muscle mass and bone density [3]. This increase in muscle mass is due to elevated growth hormone production and IGF-1 levels, which promote muscle growth and recovery [4]. MK-677 also stimulates ghrelin receptors, which increases one's appetite, making it easier to achieve a caloric surplus.

However, it's important to note that while MK-677 can increase muscle mass, it does not necessarily increase strength or endurance, which raises questions about whether it is a performance-enhancing drug [3].

It's worth noting that body composition changes may not benefit all individuals, particularly those aiming for a lean physique.

Searching for the answer?

Let's be honest, you just wanted a quick, direct answer to your question. That's why we createdMediSearch- a free, science-based search for medical information.

Does MK-677 need PCT?

Based on the provided studies, no direct evidence suggests that MK-677, an oral ghrelin mimetic, requires PCT. The evidence supporting the use of PCT after performance-enhancing drugs is also anecdotal [1]. Since MK-677 changes body composition without directly affecting strength, it is controversial whether MK-677 is a performance-enhancing drug.

In light of this, popular resources suggest that MK-677 should be used during PCT to harness your body's growth hormone and thereby increase recovery after a cycle of steroids. Nonetheless, there is no evidence to support this claim, so it is not recommended to take MK-677 during PCT, as it may hamper your recovery and exacerbate side effects.


It's recommended to consult with a healthcare professional before starting or ending any regimen involving substances like MK-677. MK-677 is a banned substance in competitive sport and is not FDA-approved.

Related Posts

Klara Hatinova

Klara Hatinova

Klara is a postgraduate researcher in experimental psychology at the University of Oxford. She has worked across a spectrum of hot topics in neuroscience, including her current project measuring reinforcement learning strategies in Parkinson’s disease. Previously, she studied the efficacy of psilocybin as a therapy for critical mental health conditions and examined molecular circadian rhythms of migraine disorders. She completed her undergraduate degree in Neuroscience at the University of Glasgow and participated in a year abroad at the University of California, where she worked on a clinical trial for spinal cord injury.